PE20230834A1 - Antagonistas del receptor de lpa y usos de los mismos - Google Patents

Antagonistas del receptor de lpa y usos de los mismos

Info

Publication number
PE20230834A1
PE20230834A1 PE2022002823A PE2022002823A PE20230834A1 PE 20230834 A1 PE20230834 A1 PE 20230834A1 PE 2022002823 A PE2022002823 A PE 2022002823A PE 2022002823 A PE2022002823 A PE 2022002823A PE 20230834 A1 PE20230834 A1 PE 20230834A1
Authority
PE
Peru
Prior art keywords
alkyl
optionally substituted
independently selected
compounds
lpar1
Prior art date
Application number
PE2022002823A
Other languages
English (en)
Inventor
Brian P Bestvater
Zhimin Du
Julie Farand
Joshua A Kaplan
Barton W Phillips
Doris T Tang
Chandrasekar Venkataramani
Peiyuan Wang
Kin S Yang
Anna Zagorska
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20230834A1 publication Critical patent/PE20230834A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgacion se refiere a un compuesto de formula (I), o una sal farmaceuticamente aceptable del mismo, en donde: R1 es H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, entre otros; R2 es H o alquilo C1-6 opcionalmente sustituido, entre otros; cada R3 se selecciona independientemente de deuterio, H, alquilo C1-6, entre otros; n es 0, 1, 2, 3, o 4; R4 es alquilo C1-6 opcionalmente sustituido con 1 a 3 sustituyentes seleccionados independientemente de halogeno, ciano, alcoxi C1-4, entre otros; cada uno de X1, X2, X3 y X4 se selecciona independientemente de CH y N; cada Y1 y Y2 es independientemente H, deuterio o alquilo C1-6 opcionalmente sustituido; Z es alquilo C1-8, alcoxi C1-6, cicloalquilo C3-6, entre otros. Un compuesto seleccionado es (R)-1-(3-fluorofenil)etil(1-metil-4-(4-(2,2,2-trifluoroacetamido)fenil)-1H-1,2,3-triazol-5-il)carbamato. Dichos compuestos son inhibidores del receptor de acido lisofosfatidico 1 (LPAR1). Tambien se refiere a metodos de preparacion de dichos compuestos, compuestos intermediarios y una composicion farmaceutica que lo comprende; siendo utiles para el tratamiento de enfermedades y/o afecciones mediante la union de LPAR1, que incluyen fibrosis y enfermedades hepaticas como esteatohepatitis no alcoholica (NASH), enfermedad pulmonar intersticial (ILD), o enfermedad renal cronica (ERC).
PE2022002823A 2020-06-03 2021-05-13 Antagonistas del receptor de lpa y usos de los mismos PE20230834A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034220P 2020-06-03 2020-06-03
US202063130242P 2020-12-23 2020-12-23
PCT/US2021/032293 WO2021247217A1 (en) 2020-06-03 2021-05-13 Lpa receptor antagonists and uses thereof

Publications (1)

Publication Number Publication Date
PE20230834A1 true PE20230834A1 (es) 2023-05-19

Family

ID=76250497

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002823A PE20230834A1 (es) 2020-06-03 2021-05-13 Antagonistas del receptor de lpa y usos de los mismos

Country Status (16)

Country Link
US (2) US11584738B2 (es)
EP (1) EP4161641A1 (es)
KR (1) KR20230019881A (es)
CN (1) CN115942972A (es)
AU (1) AU2021285747A1 (es)
BR (1) BR112022024348A2 (es)
CA (1) CA3183097A1 (es)
CL (1) CL2022003395A1 (es)
CO (1) CO2022017226A2 (es)
CR (1) CR20220609A (es)
DO (1) DOP2022000269A (es)
IL (1) IL298082A (es)
MX (1) MX2022015243A (es)
PE (1) PE20230834A1 (es)
WO (1) WO2021247217A1 (es)
ZA (1) ZA202212223B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113711036A (zh) 2019-01-30 2021-11-26 真和制药有限公司 抗gal3抗体及其用途
WO2022109598A1 (en) * 2020-11-19 2022-05-27 Pliant Therapeutics, Inc. Integrin inhibitor and uses thereof
TWI818538B (zh) 2021-05-11 2023-10-11 美商基利科學股份有限公司 Ｌｐａ受體拮抗劑及其用途
WO2022241023A1 (en) * 2021-05-13 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN114524812A (zh) * 2022-03-18 2022-05-24 湖南凯铂生物药业有限公司 1,4-二氢-1,6-萘啶化合物的晶型制备以及合成方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2002002460A0 (en) 2001-03-09 2002-06-30 Pfizer Prod Inc Novel benzimidazole anti-inflammatory compounds.
JP4653660B2 (ja) 2003-09-04 2011-03-16 独立行政法人理化学研究所 ＴＧＦ−β活性化制御領域の切断面を認識する抗体
US20070276050A1 (en) 2006-02-27 2007-11-29 Gilead Sciences, Inc. Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases
CN102083432B (zh) 2008-05-05 2016-02-17 赛诺菲-安万特 酰基氨基取代的稠合环戊烷羧酸衍生物及它们作为药物的用途
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
WO2011037192A1 (ja) 2009-09-25 2011-03-31 アステラス製薬株式会社 置換アミド化合物
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
WO2011159550A2 (en) 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159632A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
KR101769654B1 (ko) 2010-09-24 2017-08-18 아스텔라스세이야쿠 가부시키가이샤 치환 아미드 화합물
CN103596566B (zh) 2010-12-07 2017-08-25 阿米拉制药公司 多环lpa1拮抗剂及其使用
SG190417A1 (en) 2010-12-07 2013-07-31 Amira Pharmaceuticals Inc Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
US8785442B2 (en) 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
US8541587B2 (en) 2011-04-05 2013-09-24 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
SI3329919T1 (sl) 2011-11-11 2020-02-28 Gilead Apollo, Llc Inhibitorji ACC in njihove uporabe
US20140329871A1 (en) 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
US9518112B2 (en) 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
MX2014014105A (es) 2012-06-20 2015-03-05 Hoffmann La Roche Compuestos de pirazol sustituidos como antagonistas del receptor del acido lisofosfatidico (lpar).
PE20142448A1 (es) 2012-06-20 2015-01-28 Hoffmann La Roche Compuestos de n-alquiltriazol como antagonistas de lpar
UA110310C2 (uk) 2012-06-20 2015-12-10 Ф. Хоффманн-Ля Рош Аг Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
CA2877184A1 (en) 2012-09-05 2014-03-13 F. Hoffmann-La Roche Ag Lpar-substituted cyanopyrazole compounds
ES2637407T3 (es) 2012-11-09 2017-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Nuevos compuestos de bencenosulfonamida tiazol
WO2014104372A1 (ja) 2012-12-28 2014-07-03 宇部興産株式会社 ハロゲン置換へテロ環化合物
WO2014113485A1 (en) * 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
ES2855173T3 (es) 2013-03-15 2021-09-23 Epigen Biosciences Inc Compuestos heterocíclicos útiles para el tratamiento de una enfermedad
WO2014182945A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
CN105658666B (zh) 2013-08-01 2021-07-27 鲁汶大学 抗garp蛋白及其用途
GB201314926D0 (en) 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds
EP3062827A1 (en) 2013-10-31 2016-09-07 Bristol-Myers Squibb Company Radioligands for imaging the lpa-1 receptor
RU2689315C2 (ru) 2014-06-27 2019-05-27 Убе Индастриз, Лтд. Соль гетероциклического соединения, замещенного галогеном
SG10201906471PA (en) 2015-01-14 2019-09-27 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
CA3005811A1 (en) 2015-11-20 2017-05-26 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of nash
TWI788281B (zh) 2016-03-02 2023-01-01 美商基利阿波羅有限責任公司 噻吩并嘧啶二酮acc抑制劑之固體型式及其製造方法
AR108185A1 (es) 2016-04-06 2018-07-25 Abbvie Inc Amidas terciarias y método para su uso
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AU2018205231A1 (en) 2017-01-06 2019-07-18 Scholar Rock, Inc. Isoform-specific, context-permissive TGFβ1 inhibitors and use thereof
WO2019041340A1 (en) 2017-09-04 2019-03-07 Eli Lilly And Company LYSOPHOSPHATIDE ACID RECEPTOR 1 RECEPTOR INHIBITORS (LPAR1)
WO2019113123A1 (en) 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
EP3728210A1 (en) 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
CN112041029A (zh) 2017-12-19 2020-12-04 百时美施贵宝公司 作为lpa拮抗剂的环己基酸吡唑唑类
EP3728242B1 (en) 2017-12-19 2023-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
EA202091506A1 (ru) 2017-12-19 2020-09-22 Бристол-Маерс Сквибб Компани Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa
ES2938863T3 (es) 2017-12-19 2023-04-17 Bristol Myers Squibb Co Triazol azoles de ácido ciclohexilo como antagonistas de ácido lisofosfatídico (LPA)
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
CA3085347A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
CN112055711A (zh) 2017-12-19 2020-12-08 百时美施贵宝公司 作为lpa拮抗剂的环己基酸三唑吖嗪类
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
CN112055710A (zh) 2017-12-19 2020-12-08 百时美施贵宝公司 作为lpa拮抗剂的环己基酸吡唑吖嗪
KR20200100752A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 피라졸 o-연결된 카르바모일 시클로헥실 산
US20220041572A1 (en) 2018-09-18 2022-02-10 Bristol-Myers Squibb Company Cycloheptyl acids as lpa antagonists
CN113366000A (zh) 2018-09-18 2021-09-07 百时美施贵宝公司 作为lpa拮抗剂的氧杂双环酸
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN113260310A (zh) 2018-10-15 2021-08-13 百时美施贵宝公司 用于成像lpa1受体的放射性配体
CN114599640A (zh) 2019-06-18 2022-06-07 百时美施贵宝公司 作为lpa拮抗剂的异噁唑羧酸
EP3986551A1 (en) 2019-06-18 2022-04-27 Bristol-Myers Squibb Company Triazole carboxylic acids as lpa antagonists
US20220235027A1 (en) 2019-06-18 2022-07-28 Bristol-Myers Squibb Company Cyclobutyl carboxylic acids as lpa antagonists
US20230097871A1 (en) 2019-07-30 2023-03-30 Taisho Pharmaceutical Co., Ltd. Urea compound for antagonizing lpa1 receptor
KR20220101137A (ko) 2019-11-15 2022-07-19 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
US20230000846A1 (en) 2019-12-04 2023-01-05 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
JP2023529369A (ja) 2020-06-03 2023-07-10 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
WO2022013378A1 (en) 2020-07-16 2022-01-20 Chiesi Farmaceutici S.P.A. Amido cyclohexane acid derivatives as lpa receptor inhibitors
CN116669727A (zh) 2020-08-11 2023-08-29 唯久生物有限公司 作为lpa受体拮抗剂的三唑-吡啶基取代的氮杂环己基乙酸化合物
CN114456147A (zh) 2020-11-10 2022-05-10 武汉人福创新药物研发中心有限公司 氧取代氨基碳酸酯噻吩类化合物
CN114456157A (zh) 2020-11-10 2022-05-10 武汉人福创新药物研发中心有限公司 氮取代氨基碳酸酯噻吩类化合物及其用途
WO2022100623A1 (zh) 2020-11-10 2022-05-19 武汉人福创新药物研发中心有限公司 氮取代杂环噻吩类化合物及其用途
WO2022174883A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
WO2022174882A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
TWI818538B (zh) 2021-05-11 2023-10-11 美商基利科學股份有限公司 Ｌｐａ受體拮抗劑及其用途
WO2022241023A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof

Also Published As

Publication number Publication date
AU2021285747A8 (en) 2023-02-23
DOP2022000269A (es) 2023-01-15
TW202204340A (zh) 2022-02-01
EP4161641A1 (en) 2023-04-12
ZA202212223B (en) 2023-07-26
KR20230019881A (ko) 2023-02-09
US11584738B2 (en) 2023-02-21
MX2022015243A (es) 2023-01-11
JP2023527878A (ja) 2023-06-30
BR112022024348A2 (pt) 2022-12-27
WO2021247217A1 (en) 2021-12-09
TW202344504A (zh) 2023-11-16
CN115942972A (zh) 2023-04-07
US20230212151A1 (en) 2023-07-06
AU2021285747A1 (en) 2023-01-19
IL298082A (en) 2023-01-01
US11912686B2 (en) 2024-02-27
US20230012262A1 (en) 2023-01-12
CL2022003395A1 (es) 2023-05-26
CR20220609A (es) 2023-05-04
CA3183097A1 (en) 2021-12-09
CO2022017226A2 (es) 2023-02-16

Similar Documents

Publication Publication Date Title
PE20230834A1 (es) Antagonistas del receptor de lpa y usos de los mismos
PE20210655A1 (es) Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa
AR071314A1 (es) Antagonistas de receptor de cgrp
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
AR061243A1 (es) Derivados de n-2-feniletil-carboxamidas, composiciones para el control de mocroorganismos fitopatogenicos que los comprenden y un metodo de control o prevencion de infestacion de plantas utiles que los emplea.
AR074676A1 (es) Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa.
PE20060076A1 (es) Antagonistas del receptor de acetilcolina muscarinico
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
RU2014149183A (ru) Проницаемые ингибиторы гликозидазы и их применения
PE20170024A1 (es) Compuestos de 6,8-dioxabiciclo [3.2.1] octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
PE20180799A1 (es) Reguladores de nrf2
JP2015516420A5 (es)
RU2013130250A (ru) Замещенные пуриновые и 7-деазапуриновые соединения
PE20051170A1 (es) DERIVADOS DE PIRROL COMO INHIBIDORES DEL FACTOR Xa
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
JP2019519616A5 (es)
PE20060121A1 (es) Compuestos amidas biciclicos como antagonistas del receptor de acetilcolina muscarinico m3
JP2012510502A5 (es)
AR083872A1 (es) Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep
US9073901B2 (en) DGAT2 inhibitors
PE20081164A1 (es) Nuevos compuestos 521
AR055431A1 (es) Derivados del acido 4-amino-tieno[3,2-c]piridina-7-carboxilico
RU2013128968A (ru) Соединения, активные в отношении кальций-чувствительного рецептора
JP2015536997A5 (es)